Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study

Journal of Crohn's and Colitis

Volumn 8, Issue 2, 2014, Pages 161-165

  Babouri, Abdenour ^a   Roblin, Xavier ^b   Filippi, JérÔme ^c   Hébuterne, Xavier ^c   Bigard, Marc André ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Acute reactions; Delayed reactions; Inflammatory bowel disease; Infliximab; One hour infusions

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CORTICOSTEROID; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; RETINOID; STEROID;

ACNE; ADULT; ANAPHYLAXIS; ARTICLE; ASTHENIA; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOOT AND MOUTH DISEASE; HUMAN; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; LUPUS VULGARIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHARYNGITIS; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINUSITIS; SKIN DEFECT; STANDARD; ULCERATIVE COLITIS;

ACUTE REACTIONS; DELAYED REACTIONS; INFLAMMATORY BOWEL DISEASE; INFLIXIMAB; ONE HOUR INFUSIONS;

ACNE VULGARIS; ADULT; AGED; ANAPHYLAXIS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG ERUPTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84892869093     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.08.004     Document Type: Article

References (19)

1. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
2. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
3. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
4. Sands B.E., Blank M.A., Patel K., van Deventer S.J. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004, 2:912-920. [287].
5. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
6. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
7. Buch M.H., Bryer D., Lindsay S., Rees-Evans B., Fairclough A., Emery P. Shortening infusion times for infliximab administration. Rheumatology (Oxford) 2006, 45:485-486.
8. Breynaert C., Ferrante M., Fidder H., Van Steen K., Noman M., Ballet V., et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 2011, 106:778-785.
9. Van Assche G., Vermeire S., Noman M., Amant C., Weyts E., Vleminckx A., et al. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. J Crohns Colitis 2010, 4:329-333.
10. REMICADE SPC [3236 Read on Aug 17, 2011]. http://www.medicines.org.uk/emc/medicine/.
11. Babouri A., et al. Tolerability of one hour1h 10mg/kg infliximab infusions in patients with inflammatory bowel disease. J Crohns Colitis 2012, 7:129-133.
12. Cheifetz A., Smedley M., Martin S., Reiter M., Leone G., Mayer L., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003, 98:1315-1324.
13. Peyrin-Biroulet L., Oussalah A., Williet N., Pillot C., Bresler L., Bigard M.A. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011, 60:930-936.
14. Williet N., Pillot C., Oussalah A., Billioud V., Chevaux J.-B., Bresler L., et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis 2012, 18:1641-1646.
15. Peyrin-Biroulet L., Pillot C., Oussalah A., Billioud V., Aissa N., Balde M., et al. Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience. Inflamm Bowel Dis 2012, 18:697-702.
16. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
17. Van Vollenhoven R.F., Gullström E., Klareskog L. Feasibility of 1hour infliximab infusions. Ann Rheum Dis 2005, 64:654.
18. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 1999, 354:1932-1939.
19. Neef H.C., Riebschleger M.P., Adler J. Meta-analysis: rapid infliximab infusions are safe. Aliment Pharmacol Ther 2013, 38:365-376.